Bristol-Myers Squibb (BMY)
Abstract No. 4Indication: melanoma Clinical Trial: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. Presentation Time:Sunday, June 6. ASCO Plenary Session. Notes:Bristol gained full ownership of ipilimumab when it acquired Medarex in 2009. ASCO did not release the research abstract Thursday night.